|
US2008213267A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
US2008213169A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
|
US2008124327A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
US2008089891A1
|
|
Cancerous disease modifying antibodies
|
|
US2008131429A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
US2008131428A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
US2008025977A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
|
US2007202113A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
WO2007095745A1
|
|
Cancerous disease modifying antibody 141205-02
|
|
US2007202041A1
|
|
Cancerous disease modifying antibodies
|
|
US2006263372A1
|
|
Cancerous disease modifying antibodies
|
|
US2007031427A1
|
|
Cancerous disease modifying antibodies
|
|
US2007031428A1
|
|
Cancerous disease modifying antibodies
|
|
US2007031426A1
|
|
Cancerous disease modifying antibodies
|
|
US2007031429A1
|
|
Cancerous disease modifying antibodies
|
|
US2007031425A1
|
|
Cancerous disease modifying antibodies
|
|
US2006216234A1
|
|
Antibody therapy of tumors
|
|
US2007025912A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US2006140963A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
|
US2006204497A1
|
|
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
